Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions
AXSM Stock Forecast
Axsome Therapeutics stock forecast is as follows: an average price target of $122.42 (represents a 24.68% upside from AXSM’s last price of $98.19) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
AXSM Price Target
The average price target for Axsome Therapeutics (AXSM) is $122.42 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $85.00. This represents a potential 24.68% upside from AXSM's last price of $98.19.
AXSM Analyst Ratings
According to 14 Wall Street analysts, Axsome Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AXSM stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 1 'Hold' (7.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Axsome Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | Yatin Suneja | Guggenheim | - | - | 35.69% | 37.49% |
| Sep 11, 2024 | Graig Suvannavejh | Mizuho Securities | - | - | 17.03% | 7.95% |
| Sep 03, 2024 | Cerena Chen | Wells Fargo | - | - | 57.55% | 42.58% |
| Aug 06, 2024 | Raghuram Selvaraju | H.C. Wainwright | - | - | 116.32% | 83.32% |
| Aug 06, 2024 | Jason Gerberry | Bank of America Securities | - | - | 26.30% | 7.95% |
| Jul 22, 2024 | Leonid Timashev | RBC Capital | - | - | 54.39% | 33.41% |
| Jun 05, 2024 | Leonid Timashev | RBC Capital | - | - | 79.96% | 32.40% |
| May 28, 2024 | David Amsellem | Piper Sandler | - | - | 52.95% | 17.12% |
| Apr 29, 2024 | Vikram Purohit | Morgan Stanley | - | - | 55.11% | 17.12% |
| Mar 28, 2024 | Graig Suvannavejh | Mizuho Securities | - | - | 37.68% | 11.01% |
The latest Axsome Therapeutics stock forecast, released on Nov 12, 2024 by Yatin Suneja from Guggenheim, set a price target of $135.00, which represents a 35.69% increase from the stock price at the time of the forecast ($99.49), and a 37.49% increase from AXSM last price ($98.19).
Axsome Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 11 |
| Avg Price Target | $135.00 | $127.00 | $125.00 |
| Last Closing Price | $98.19 | $98.19 | $98.19 |
| Upside/Downside | 37.49% | 29.34% | 27.30% |
In the current month, the average price target of Axsome Therapeutics stock is $135.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 37.49% increase as opposed to Axsome Therapeutics's last price of $98.19. This month's average price target is up 6.30% compared to last quarter, and up 8.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 04, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 04, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 09, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Wells Fargo | Buy | Overweight | Initialise |
| Aug 23, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 22, 2024 | UBS | Buy | Buy | Hold |
| Aug 22, 2024 | RBC Capital | Underperform | Underperform | Hold |
Axsome Therapeutics's last stock rating was published by Wells Fargo on Oct 04, 2024. The company gave AXSM a "Buy" rating, the same as its previous rate.
Axsome Therapeutics Financial Forecast
Axsome Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $57.79M | $46.70M | $94.58M | $24.37M | $16.85M | $8.82M |
| Avg Forecast | $365.35M | $312.69M | $262.05M | $199.78M | $213.47M | $166.98M | $142.00M | $120.30M | $116.78M | $98.37M | $86.92M | $73.29M | $69.24M | $54.87M | $40.88M | $25.47M | $21.75M | $16.64M | $6.92M |
| High Forecast | $390.95M | $334.60M | $280.41M | $213.78M | $228.42M | $178.68M | $151.95M | $127.22M | $124.89M | $99.36M | $86.92M | $73.29M | $70.60M | $60.04M | $43.74M | $27.26M | $23.28M | $16.64M | $6.92M |
| Low Forecast | $334.03M | $285.88M | $239.58M | $182.65M | $195.16M | $152.66M | $129.83M | $108.42M | $107.00M | $97.38M | $86.92M | $73.29M | $66.51M | $48.88M | $37.37M | $23.29M | $19.89M | $16.64M | $6.92M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.14% | 3.71% | 1.12% | 1.01% | 1.27% |
Axsome Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $69.24M, with a low forecast of $66.51M, and a high forecast of $70.60M. AXSM's average Quarter revenue forecast represents a 19.81% increase compared to the company's last Quarter revenue of $57.79M (Sep 23).
Axsome Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-62.12M | $-65.06M | $-4.96M | $-53.70M | $-40.49M | $-38.77M |
| Avg Forecast | $85.39M | $73.08M | $61.24M | $46.69M | $49.89M | $39.02M | $33.19M | $28.12M | $27.29M | $22.99M | $20.31M | $17.13M | $16.18M | $12.82M | $9.55M | $5.95M | $5.08M | $4.49M | $1.87M |
| High Forecast | $91.37M | $78.20M | $65.53M | $49.96M | $53.38M | $41.76M | $35.51M | $29.73M | $29.19M | $23.22M | $20.31M | $17.13M | $16.50M | $14.03M | $10.22M | $6.37M | $5.44M | $4.49M | $1.87M |
| Low Forecast | $78.07M | $66.81M | $55.99M | $42.69M | $45.61M | $35.68M | $30.34M | $25.34M | $25.01M | $22.76M | $20.31M | $17.13M | $15.54M | $11.42M | $8.73M | $5.44M | $4.65M | $4.49M | $1.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.84% | -6.81% | -0.83% | -10.56% | -9.02% | -20.77% |
undefined analysts predict AXSM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Axsome Therapeutics's previous annual EBITDA (undefined) of $NaN.
Axsome Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-62.20M | $-67.17M | $-11.22M | $-66.76M | $-47.23M | $-42.84M |
| Avg Forecast | $108.95M | $74.19M | $41.06M | $1.81M | $17.08M | $-13.85M | $-29.46M | $-45.13M | $-47.46M | $-66.60M | $-62.93M | $-57.99M | $-56.39M | $-57.93M | $-58.42M | $-62.77M | $-54.20M | $-49.96M | $-47.86M |
| High Forecast | $118.88M | $80.95M | $44.80M | $1.97M | $18.64M | $-12.31M | $-26.17M | $-30.09M | $-22.05M | $-59.18M | $-55.91M | $-51.52M | $-50.33M | $-45.27M | $-51.91M | $-55.78M | $-48.16M | $-49.96M | $-47.86M |
| Low Forecast | $96.81M | $65.93M | $36.48M | $1.60M | $15.18M | $-15.12M | $-32.14M | $-60.18M | $-65.68M | $-72.67M | $-68.66M | $-63.27M | $-68.04M | $-64.74M | $-63.74M | $-68.49M | $-59.14M | $-49.96M | $-47.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.15% | 0.18% | 1.23% | 0.95% | 0.89% |
Axsome Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AXSM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Axsome Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.19M | $78.94M | $74.19M | $61.50M | $40.89M | $31.16M |
| Avg Forecast | $539.03M | $461.33M | $386.61M | $294.74M | $314.94M | $246.35M | $209.50M | $177.49M | $172.29M | $145.13M | $128.24M | $108.13M | $102.16M | $80.95M | $60.31M | $37.58M | $32.09M | $24.54M | $10.21M |
| High Forecast | $576.80M | $493.66M | $413.70M | $315.40M | $337.01M | $263.62M | $224.19M | $187.69M | $184.25M | $146.59M | $128.24M | $108.13M | $104.16M | $88.57M | $64.54M | $40.21M | $34.34M | $24.54M | $10.21M |
| Low Forecast | $492.81M | $421.78M | $353.47M | $269.47M | $287.94M | $225.23M | $191.54M | $159.95M | $157.86M | $143.67M | $128.24M | $108.13M | $98.12M | $72.12M | $55.14M | $34.36M | $29.34M | $24.54M | $10.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.31% | 1.97% | 1.92% | 1.67% | 3.05% |
Axsome Therapeutics's average Quarter SG&A projection for Dec 23 is $102.16M, based on 7 Wall Street analysts, with a range of $98.12M to $104.16M. The forecast indicates a 22.80% rise compared to AXSM last annual SG&A of $83.19M (Sep 23).
Axsome Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.32 | $-0.00 | $-0.26 | $-1.54 | $-1.13 | $-1.10 |
| Avg Forecast | $2.26 | $1.54 | $0.85 | $0.04 | $0.35 | $-0.29 | $-0.61 | $-0.94 | $-0.99 | $-1.38 | $-1.31 | $-1.20 | $-1.17 | $-1.20 | $-1.21 | $-1.30 | $-1.13 | $-1.05 | $-1.01 |
| High Forecast | $2.47 | $1.68 | $0.93 | $0.04 | $0.39 | $-0.26 | $-0.54 | $-0.63 | $-0.46 | $-1.23 | $-1.16 | $-1.07 | $-1.05 | $-0.94 | $-1.08 | $-1.16 | $-1.00 | $-1.05 | $-1.01 |
| Low Forecast | $2.01 | $1.37 | $0.76 | $0.03 | $0.32 | $-0.31 | $-0.67 | $-1.25 | $-1.36 | $-1.51 | $-1.43 | $-1.31 | $-1.41 | $-1.34 | $-1.32 | $-1.42 | $-1.23 | $-1.05 | $-1.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 0.00% | 0.20% | 1.37% | 1.08% | 1.09% |
According to undefined Wall Street analysts, Axsome Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AXSM previous annual EPS of $NaN (undefined).
Axsome Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | - | - | 10044.93% | Buy |
| PDSB | PDS Bio | - | - | 309.09% | Buy |
| DAWN | Day One Biopharmaceuticals | - | - | 190.85% | Buy |
| TERN | Terns Pharmaceuticals | - | - | 149.56% | Buy |
| VKTX | Viking Therapeutics | - | - | 98.33% | Buy |
| MCRB | Seres Therapeutics | - | - | 71.23% | Buy |
| ACAD | ACADIA Pharmaceuticals | - | - | 64.22% | Buy |
| SRPT | Sarepta Therapeutics | - | - | 53.00% | Buy |
| AKRO | Akero Therapeutics | - | - | 47.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | - | - | 28.52% | Buy |
| AXSM | Axsome Therapeutics | - | - | 24.68% | Buy |
| INCY | Incyte | - | - | 20.13% | Buy |
| BPMC | Blueprint Medicines | - | - | 13.55% | Buy |
| MDGL | Madrigal Pharmaceuticals | - | - | -4.10% | Buy |
| TGTX | TG Therapeutics | - | - | -20.12% | Buy |